229 related articles for article (PubMed ID: 35237863)
1. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
2. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
3. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
5. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
8. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
[TBL] [Abstract][Full Text] [Related]
9. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
10. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
11. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
[TBL] [Abstract][Full Text] [Related]
12. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
[TBL] [Abstract][Full Text] [Related]
14. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
15. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
16. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
[TBL] [Abstract][Full Text] [Related]
17. Associations between anemia and FGF23 in the CKiD study.
Thomas E; Klomhaus AM; Laster ML; Furth SL; Warady BA; Salusky IB; Hanudel MR
Pediatr Nephrol; 2024 Mar; 39(3):837-847. PubMed ID: 37752381
[TBL] [Abstract][Full Text] [Related]
18. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
[TBL] [Abstract][Full Text] [Related]
19. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
[TBL] [Abstract][Full Text] [Related]
20. Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto M; Suematsu Y; Nunes ACF; Jing W; Khazaeli M; Lau WL; Vaziri ND
Iran J Kidney Dis; 2019 Mar; 13(2):98-104. PubMed ID: 30988246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
